Ignet

Gene Information

Gene symbol: PLP1

Gene name: proteolipid protein 1

HGNC ID: 9086

Related Genes

#	Gene Symbol	Number of hits
1	AHI1	1 hits
2	APC	1 hits
3	APOE	1 hits
4	CADM1	1 hits
5	CD40	1 hits
6	CD80	1 hits
7	CD86	1 hits
8	HLA-A	1 hits
9	IFNG	1 hits
10	IL17A	1 hits
11	IL2	1 hits
12	IL23A	1 hits
13	IL4	1 hits
14	MBP	1 hits
15	MET	1 hits
16	MOG	1 hits
17	PLP2	1 hits
18	PPIC	1 hits
19	TNF	1 hits

Related Sentences

#	PMID	Sentence
1	2480399	In this study we detected MBP and PLP in the vaccine using immunological methods.
2	3491156	T cell lines specific for bovine myelin proteolipid apoprotein (PLP) were established from SJL/J mice.
3	3491156	The line cells bore surface phenotypes of T helper/inducer cells (Lyt-1+, Lyt-2-, L3T4+) and responded well to bovine, rat, and guinea pig PLP but not to myelin basic protein.
4	3491156	T cell lines specific for bovine myelin proteolipid apoprotein (PLP) were established from SJL/J mice.
5	3491156	The line cells bore surface phenotypes of T helper/inducer cells (Lyt-1+, Lyt-2-, L3T4+) and responded well to bovine, rat, and guinea pig PLP but not to myelin basic protein.
6	8833909	In patients with the demyelinating disease multiple sclerosis (MS), multiple potentially autoantigenic epitopes have been identified on the two major proteins of the myelin sheath, myelin basic protein (MBP) and proteolipid protein (PLP).
7	8833909	To generate a tolerogenic protein for the therapy of patients with MS, we have produced a protein fusion between the 21.5-kD isoform of MBP (MBP21.5) and a genetically engineered form of PLP (deltaPLP4).
8	8833909	Importantly, the administration of MP4 completely suppressed the development of EAE initiated by the cotransfer of both MBP- and PLP-activated T cells.
9	8833909	Prevention of clinical disease after the intravenous injection of MP4 was paralleled by the formation of long-lived functional peptide-MHC complexes in vivo, as well as by a significant reduction in both MBP- and PLP-specific T cell proliferative responses.
10	8833909	In patients with the demyelinating disease multiple sclerosis (MS), multiple potentially autoantigenic epitopes have been identified on the two major proteins of the myelin sheath, myelin basic protein (MBP) and proteolipid protein (PLP).
11	8833909	To generate a tolerogenic protein for the therapy of patients with MS, we have produced a protein fusion between the 21.5-kD isoform of MBP (MBP21.5) and a genetically engineered form of PLP (deltaPLP4).
12	8833909	Importantly, the administration of MP4 completely suppressed the development of EAE initiated by the cotransfer of both MBP- and PLP-activated T cells.
13	8833909	Prevention of clinical disease after the intravenous injection of MP4 was paralleled by the formation of long-lived functional peptide-MHC complexes in vivo, as well as by a significant reduction in both MBP- and PLP-specific T cell proliferative responses.
14	8833909	In patients with the demyelinating disease multiple sclerosis (MS), multiple potentially autoantigenic epitopes have been identified on the two major proteins of the myelin sheath, myelin basic protein (MBP) and proteolipid protein (PLP).
15	8833909	To generate a tolerogenic protein for the therapy of patients with MS, we have produced a protein fusion between the 21.5-kD isoform of MBP (MBP21.5) and a genetically engineered form of PLP (deltaPLP4).
16	8833909	Importantly, the administration of MP4 completely suppressed the development of EAE initiated by the cotransfer of both MBP- and PLP-activated T cells.
17	8833909	Prevention of clinical disease after the intravenous injection of MP4 was paralleled by the formation of long-lived functional peptide-MHC complexes in vivo, as well as by a significant reduction in both MBP- and PLP-specific T cell proliferative responses.
18	8833909	In patients with the demyelinating disease multiple sclerosis (MS), multiple potentially autoantigenic epitopes have been identified on the two major proteins of the myelin sheath, myelin basic protein (MBP) and proteolipid protein (PLP).
19	8833909	To generate a tolerogenic protein for the therapy of patients with MS, we have produced a protein fusion between the 21.5-kD isoform of MBP (MBP21.5) and a genetically engineered form of PLP (deltaPLP4).
20	8833909	Importantly, the administration of MP4 completely suppressed the development of EAE initiated by the cotransfer of both MBP- and PLP-activated T cells.
21	8833909	Prevention of clinical disease after the intravenous injection of MP4 was paralleled by the formation of long-lived functional peptide-MHC complexes in vivo, as well as by a significant reduction in both MBP- and PLP-specific T cell proliferative responses.
22	9266414	The examination of an experimental animal model for MS, experimental allergic encephalomyelitis (EAE), demonstrated that myelin basic protein-(MBP) or proteolipidprotein-(PLP) specific T cells mediate the destruction of CNS myelin.
23	9266414	In recent years, elegant studies in EAE showed that encephalitogenic T cells recognize short peptides of MBP or PLP in the context of MHC/HLA-class II molecules, express a restricted number of T cell receptor (TCR) molecules and secrete interferon-gamma and tumor necrosis factor-alpha/beta.
24	9266414	MBP- and PLP-specific T cells with similar properties could also be isolated from MS patients and control individuals.
25	9266414	The examination of an experimental animal model for MS, experimental allergic encephalomyelitis (EAE), demonstrated that myelin basic protein-(MBP) or proteolipidprotein-(PLP) specific T cells mediate the destruction of CNS myelin.
26	9266414	In recent years, elegant studies in EAE showed that encephalitogenic T cells recognize short peptides of MBP or PLP in the context of MHC/HLA-class II molecules, express a restricted number of T cell receptor (TCR) molecules and secrete interferon-gamma and tumor necrosis factor-alpha/beta.
27	9266414	MBP- and PLP-specific T cells with similar properties could also be isolated from MS patients and control individuals.
28	9266414	The examination of an experimental animal model for MS, experimental allergic encephalomyelitis (EAE), demonstrated that myelin basic protein-(MBP) or proteolipidprotein-(PLP) specific T cells mediate the destruction of CNS myelin.
29	9266414	In recent years, elegant studies in EAE showed that encephalitogenic T cells recognize short peptides of MBP or PLP in the context of MHC/HLA-class II molecules, express a restricted number of T cell receptor (TCR) molecules and secrete interferon-gamma and tumor necrosis factor-alpha/beta.
30	9266414	MBP- and PLP-specific T cells with similar properties could also be isolated from MS patients and control individuals.
31	9508295	PCR, using primers Plp1 and Plp2, was evaluated for the detection of DNA from Bordetella pertussis in bacterial strains and in nasopharyngeal samples from patients with a cough lasting at least 7 days.
32	9683547	Thus therapies which decrease T cells secreting IFN-gamma production or increase IL-4 production would be expected to have an ameliorating effect on MS.
33	9683547	To investigate whether the increased IL-4 secretion was myelin antigen specific, we generated 3990 short-term T cell lines to myelin basic protein (MBP), proteolipid protein (PLP), or tetanus toxoid (TT) from 31 progressive MS patients: 11 MS patients treated with CY/MP, 10 MS patients treated with MP alone, and 10 untreated MS patients.
34	9683547	We found increased frequencies of both MBP- and PLP-specific IL-4-secreting T cell lines in CY/MP-treated patients compared to untreated MS patients.
35	9683547	Thus therapies which decrease T cells secreting IFN-gamma production or increase IL-4 production would be expected to have an ameliorating effect on MS.
36	9683547	To investigate whether the increased IL-4 secretion was myelin antigen specific, we generated 3990 short-term T cell lines to myelin basic protein (MBP), proteolipid protein (PLP), or tetanus toxoid (TT) from 31 progressive MS patients: 11 MS patients treated with CY/MP, 10 MS patients treated with MP alone, and 10 untreated MS patients.
37	9683547	We found increased frequencies of both MBP- and PLP-specific IL-4-secreting T cell lines in CY/MP-treated patients compared to untreated MS patients.
38	10092787	Proliferative responses and production of the Th1 cytokines, IL-2 and IFN-gamma, were reduced in T cells responsive to PLP139-151.
39	10092787	In the brains of mice that were successfully vaccinated, mRNA for IL-2, IL-15, and IFN-gamma were reduced.
40	10092787	DNA immunization with the myelin minigene for PLP-altered expression of B7.1 (CD80), and B7.2 (CD86) on APCs in the spleen.
41	10381609	A database search for similar protein sequences revealed considerable homology of the polypeptide with the E. coli peptidyl-prolyl cis/trans isomerase and related proteins of the parvulin family.
42	10381609	A possible role of parvulin-like protein (Plp) in the virulence of epidemic typhus agent and the nature of interstrain differences are discussed.
43	12519400	The TCL showed reactivity to MBP, MOG and/or PLP as tested by Elispot and had a restricted clonality.
44	12519400	Anti-MBP/PLP/MOG reactivities remained low or were reduced in all patients.
45	12519400	The TCL showed reactivity to MBP, MOG and/or PLP as tested by Elispot and had a restricted clonality.
46	12519400	Anti-MBP/PLP/MOG reactivities remained low or were reduced in all patients.
47	14585676	A panel of recombinant lactobacilli was constructed producing myelin proteins and peptides, including human and guinea pig myelin basic protein (MBP) and proteolipid protein peptide 139-151 (PLP(139-151)).
48	14585676	Live lactobacilli expressing guinea pig MBP(72-85) fused to the marker enzyme beta-glucuronidase (beta-gluc) were also able to significantly reduce disease when administered orally.
49	15177776	We compared the potential therapeutic effect of vaccination with DNA constructs encoding two encephalitogenic proteins, PLP and MOG, on the outcome of subsequent sensitization of EAE induced in SJL/J and C57/B6 mice.
50	15177776	Early sensitization for EAE (4 weeks after DNA vaccination) caused recipient animals to develop enhanced disease with DNA-encoding PLP but not with DNA-encoding MOG.
51	15177776	Late sensitization (more than 10 weeks) resulted in an amelioration of EAE in animals vaccinated with both PLP and MOG DNA constructs.
52	15177776	Since PLP and MOG require different MHC presentation and induce different EAE models, the results point to potential differences in immune system requirements for efficient DNA-induced amelioration of the autoimmune response.
53	15177776	We compared the potential therapeutic effect of vaccination with DNA constructs encoding two encephalitogenic proteins, PLP and MOG, on the outcome of subsequent sensitization of EAE induced in SJL/J and C57/B6 mice.
54	15177776	Early sensitization for EAE (4 weeks after DNA vaccination) caused recipient animals to develop enhanced disease with DNA-encoding PLP but not with DNA-encoding MOG.
55	15177776	Late sensitization (more than 10 weeks) resulted in an amelioration of EAE in animals vaccinated with both PLP and MOG DNA constructs.
56	15177776	Since PLP and MOG require different MHC presentation and induce different EAE models, the results point to potential differences in immune system requirements for efficient DNA-induced amelioration of the autoimmune response.
57	15177776	We compared the potential therapeutic effect of vaccination with DNA constructs encoding two encephalitogenic proteins, PLP and MOG, on the outcome of subsequent sensitization of EAE induced in SJL/J and C57/B6 mice.
58	15177776	Early sensitization for EAE (4 weeks after DNA vaccination) caused recipient animals to develop enhanced disease with DNA-encoding PLP but not with DNA-encoding MOG.
59	15177776	Late sensitization (more than 10 weeks) resulted in an amelioration of EAE in animals vaccinated with both PLP and MOG DNA constructs.
60	15177776	Since PLP and MOG require different MHC presentation and induce different EAE models, the results point to potential differences in immune system requirements for efficient DNA-induced amelioration of the autoimmune response.
61	15177776	We compared the potential therapeutic effect of vaccination with DNA constructs encoding two encephalitogenic proteins, PLP and MOG, on the outcome of subsequent sensitization of EAE induced in SJL/J and C57/B6 mice.
62	15177776	Early sensitization for EAE (4 weeks after DNA vaccination) caused recipient animals to develop enhanced disease with DNA-encoding PLP but not with DNA-encoding MOG.
63	15177776	Late sensitization (more than 10 weeks) resulted in an amelioration of EAE in animals vaccinated with both PLP and MOG DNA constructs.
64	15177776	Since PLP and MOG require different MHC presentation and induce different EAE models, the results point to potential differences in immune system requirements for efficient DNA-induced amelioration of the autoimmune response.
65	15230349	Allelic genes from three Rickettsia prowazekii strains encoding parvulin-like protein (Plp), a heat-modifiable 29.5 kDa major outer membrane protein, were earlier cloned into expression vector pQE 30.
66	15230349	In this work, recombinant proteins were overproduced in E. coli, purified, and found to exhibit an expected peptidyl-prolyl cis/trans isomerase activity of a parvulin type in vitro with oligopeptide substrates.
67	15549728	IL-12 and IL-23, which share the IL-12 p40 subunit, have been ascribed central roles in many autoimmune disorders.
68	15549728	Immunization of mice with mouse IL-12 coupled to OVA or Pan DR epitope (PADRE) peptide induced Ab directed against the IL-12 p40 subunit, which prevented IFN-gamma production in response to IL-12 administration in vivo.
69	15549728	Experimental autoimmune encephalomyelitis, an IL-23-dependent disease model, induced in SJL mice with a proteolipid protein (PLP) peptide was almost undetectable after alphaIL-12 vaccination.
70	16181082	The prominent autoimmune etiology of MS is considered to be the aberrant activation of IFN-gamma-producing Th1 cells that recognize self-peptides of the myelin sheath, such as myelin basic protein (MBP) and proteolipid protein (PLP).
71	16917781	BMDCs activated with PLPs up-regulated CD40, CD80, CD86 and major histocompatibility complex (MHC) class II surface markers and produced proinflammatory cytokines.
72	16917781	Chimeric PLPs [expressing the ovalbumin (OVA)-peptides OVA(257-264) or OVA(323-339)], but not wildtype PLPs, activated OVA-specific CD8 T cells and OVA-specific CD4 T cells, respectively, indicating both MHC class I and II presentation of the peptides by antigen-presenting cells.
73	17048276	This vaccine induced the production of antibodies that blocked IL-17A bioactivity in vitro but did not react with the other IL-17 isoforms, including IL-17F.
74	17048276	To test the ability of the vaccine to confer protection against an IL-17-dependent disorder, SJL mice were vaccinated with IL-17-OVA and encephalomyelitis (EAE) was induced by proteolipid protein (PLP) peptide 139-151.
75	19230777	An open-label dose escalation study of T-cell vaccination in multiple sclerosis patients was conducted using attenuated myelin reactive T-cells (MRTC) selected with six myelin peptides, two each from MBP, PLP and MOG.
76	21774242	To investigate the expression and localization of various functional domains of ORF1 polyprotein and ORF3 protein of hepatitis E virus in host cells, the coding sequences of the various functional domains (RdRp, HEL, MET, PLP, X) of ORF1 were separately cloned into pcDNA3. 1-GFP vectors for constructing the recombinant plasmids which were verified by enzyme digestion and sequencing.
77	24718267	Mice with HSV-IL-2- and myelin oligodendrocyte glycoprotein (MOG)-induced demyelinating diseases demonstrated a similar pattern and distribution of demyelination in their brain, spinal cord (SC) and optic nerves (ONs).
78	24718267	In contrast, no demyelination was detected in the ONs of myelin basic protein (MBP)- and proteolipid protein (PLP)-injected mice.
79	24718267	Interferon-β (IFN-β) injections significantly reduced demyelination in brains of all groups, in the SCs of the MOG and MBP groups, and completely blocked it in the SCs of the PLP and HSV-IL-2 groups as well as in ONs of MOG and HSV-IL-2 groups.
80	24718267	In contrast to IFN-β treatment, IL-12p70 protected the HSV-IL-2 group from demyelination, whereas IL-4 was not effective at all in preventing demyelination.
81	24718267	Collectively, the results indicate that the HSV-IL-2 model and the MOG model complement each other and, together, provide unique insights into the heterogeneity of human MS.
82	24718267	Mice with HSV-IL-2- and myelin oligodendrocyte glycoprotein (MOG)-induced demyelinating diseases demonstrated a similar pattern and distribution of demyelination in their brain, spinal cord (SC) and optic nerves (ONs).
83	24718267	In contrast, no demyelination was detected in the ONs of myelin basic protein (MBP)- and proteolipid protein (PLP)-injected mice.
84	24718267	Interferon-β (IFN-β) injections significantly reduced demyelination in brains of all groups, in the SCs of the MOG and MBP groups, and completely blocked it in the SCs of the PLP and HSV-IL-2 groups as well as in ONs of MOG and HSV-IL-2 groups.
85	24718267	In contrast to IFN-β treatment, IL-12p70 protected the HSV-IL-2 group from demyelination, whereas IL-4 was not effective at all in preventing demyelination.
86	24718267	Collectively, the results indicate that the HSV-IL-2 model and the MOG model complement each other and, together, provide unique insights into the heterogeneity of human MS.
87	25193268	SAgAs are comprised of a hyaluronic acid backbone with cografted intercellular cell adhesion molecule-1 ligand derived from αL-integrin (CD11a237-246, "LABL") and an encephalitogenic epitope peptide of proteolipid protein (PLP139-151, "PLP").